Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BRISTOL-MYERS SQUIBB COMPLETING COMPARISONS OF SERZONE AND SSRI INCIDENCE OF SEXUAL DYSFUNCTION, ANXIETY AND SLEEP DISORDERS; RELAPSE STUDIES ONGOING

Executive Summary

Bristol-Myers Squibb is completing two trials that compare the incidence of treatment- emergent sexual dysfunction among depressed patients taking either its recently-approved antidepressant Serzone (nefazodone) or one of the selective serotonin reuptake inhibitors.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026261

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel